Keywords: Allergan, MAP Pharma, MA, Levadex, Migraine

Allergan to acquire MAP Pharmaceuticals in $958 million deal

Article | 24 January 2013

Print This

US drugmaker Allergan (NYSE: AGN) has entered into a definitive merger agreement to acquire 100% of the shares of fellow USA-based ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in